• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents.作为潜在新型抗丙型肝炎病毒药物的C-核苷的发现与合成
ACS Med Chem Lett. 2014 Apr 10;5(6):679-84. doi: 10.1021/ml500077j. eCollection 2014 Jun 12.
2
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.强效C核苷单磷酸前药GS-6620对丙型肝炎病毒复制的抑制作用
Antimicrob Agents Chemother. 2014;58(4):1930-42. doi: 10.1128/AAC.02351-13. Epub 2014 Jan 13.
3
Anti-hepatitis C virus activity of novel beta-d-2'-C-methyl-4'-azido pyrimidine nucleoside phosphoramidate prodrugs.新型β-D-2'-C-甲基-4'-叠氮嘧啶核苷亚磷酰胺前药的抗丙型肝炎病毒活性
Antivir Chem Chemother. 2009 Oct 19;20(2):99-106. doi: 10.3851/IMP1400.
4
Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents.咪唑并三嗪和吡咯并三嗪 C-核苷衍生物作为潜在的新型抗丙型肝炎病毒药物。
Bioorg Med Chem Lett. 2014 Nov 1;24(21):4984-8. doi: 10.1016/j.bmcl.2014.09.030. Epub 2014 Sep 21.
5
Current race in the development of DAAs (direct-acting antivirals) against HCV.当前 HCV（丙型肝炎病毒）直接作用抗病毒药物（DAA）的研发进展。
Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13.
6
Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.丙型肝炎病毒聚合酶抑制剂在改善丙型肝炎抗病毒治疗方面的进展。第一部分：核苷类似物。
Expert Opin Investig Drugs. 2009 Jun;18(6):709-25. doi: 10.1517/13543780902854194.
7
A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.一项关于新开发的丙型肝炎病毒细胞培养感染性克隆（HCVcc）毒株PR63cc对直接作用抗病毒药物敏感性的分析研究。
Antiviral Res. 2017 Mar;139:18-24. doi: 10.1016/j.antiviral.2016.12.009. Epub 2016 Dec 23.
8
Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection.PSI-353661的发现，一种用于治疗丙型肝炎病毒感染的新型嘌呤核苷酸前药。
ACS Med Chem Lett. 2010 Dec 17;2(2):130-5. doi: 10.1021/ml100209f. eCollection 2011 Feb 10.
9
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.一种7-脱氮腺苷类似物是一种强效且选择性的丙型肝炎病毒复制抑制剂，具有优异的药代动力学性质。
Antimicrob Agents Chemother. 2004 Oct;48(10):3944-53. doi: 10.1128/AAC.48.10.3944-3953.2004.
10
Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection.超越干扰素α：丙型肝炎病毒感染的研究性药物
Top HIV Med. 2010 Oct-Nov;18(4):132-6.

引用本文的文献

1
Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches.针对蚊媒病毒的抗病毒策略进展：细胞、病毒及免疫相关方法
Virol J. 2025 Feb 4;22(1):26. doi: 10.1186/s12985-025-02622-z.
2
Nucleoside Analogues for Chagas Disease and Leishmaniasis Therapy: Current Status and Future Perspectives.核苷类似物在恰加斯病和利什曼病治疗中的应用：现状与未来展望。
Molecules. 2024 Nov 5;29(22):5234. doi: 10.3390/molecules29225234.
3
Approaches to the synthesis of heterocyclic -nucleosides.杂环核苷的合成方法。
Russ Chem Bull. 2023;72(2):425-481. doi: 10.1007/s11172-023-3810-1. Epub 2023 Apr 12.
4
Synthetic strategies for pyrrolo[2,1-][1,2,4]triazine: the parent moiety of antiviral drug remdesivir.吡咯并[2,1-][1,2,4]三嗪的合成策略：抗病毒药物瑞德西韦的母体部分。
Chem Heterocycl Compd (N Y). 2020;56(12):1517-1522. doi: 10.1007/s10593-020-02844-9. Epub 2021 Jan 4.
5
Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.C-7-炔基化和芳基化吡咯并三嗪C-核糖核苷的合成及其抗肿瘤活性
ACS Med Chem Lett. 2020 Jul 9;11(8):1605-1610. doi: 10.1021/acsmedchemlett.0c00269. eCollection 2020 Aug 13.
6
Recent advances in synthetic approaches for medicinal chemistry of C-nucleosides.C-核苷药物化学合成方法的最新进展。
Beilstein J Org Chem. 2018 Apr 5;14:772-785. doi: 10.3762/bjoc.14.65. eCollection 2018.

本文引用的文献

1
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.强效C核苷单磷酸前药GS-6620对丙型肝炎病毒复制的抑制作用
Antimicrob Agents Chemother. 2014;58(4):1930-42. doi: 10.1128/AAC.02351-13. Epub 2014 Jan 13.
2
Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620.抗丙型肝炎病毒核苷酸前药GS-6620的代谢与药代动力学
Antimicrob Agents Chemother. 2014;58(4):1943-51. doi: 10.1128/AAC.02350-13. Epub 2014 Jan 13.
3
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.索磷布韦联合利巴韦林治疗治疗特征不佳的丙型肝炎 1 型患者：一项随机临床试验。
JAMA. 2013 Aug 28;310(8):804-11. doi: 10.1001/jama.2013.109309.
4
Hepatitis C virus: standard-of-care treatment.丙型肝炎病毒：标准治疗方案
Adv Pharmacol. 2013;67:169-215. doi: 10.1016/B978-0-12-405880-4.00005-6.
5
Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients.发现首个 C-核苷 HCV 聚合酶抑制剂（GS-6620），在 HCV 感染患者中展现出抗病毒应答。
J Med Chem. 2014 Mar 13;57(5):1812-25. doi: 10.1021/jm400201a. Epub 2013 May 1.
6
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.治疗丙型肝炎：现行的标准护理和新兴的直接作用抗病毒药物。
J Viral Hepat. 2012 Jul;19(7):449-64. doi: 10.1111/j.1365-2893.2012.01617.x.
7
Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.2'-C-Me 取代的 C-核苷类似物的合成与表征及其作为 HCV 聚合酶抑制剂的研究。
Bioorg Med Chem Lett. 2012 Jun 15;22(12):4127-32. doi: 10.1016/j.bmcl.2012.04.065. Epub 2012 Apr 20.
8
Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.丙型肝炎病毒NS5B RNA依赖性RNA聚合酶的核苷、核苷酸及非核苷抑制剂。
J Med Chem. 2012 Mar 22;55(6):2481-531. doi: 10.1021/jm201384j. Epub 2012 Jan 23.
9
A facile synthetic approach to 7-deazaguanine nucleosides via a Boc protection strategy.一种通过Boc保护策略合成7-脱氮鸟嘌呤核苷的简便方法。
Org Lett. 2009 Jun 4;11(11):2465-8. doi: 10.1021/ol9007537.
10
The global burden of hepatitis C.丙型肝炎的全球负担。
Liver Int. 2009 Jan;29 Suppl 1:74-81. doi: 10.1111/j.1478-3231.2008.01934.x.

作为潜在新型抗丙型肝炎病毒药物的C-核苷的发现与合成

Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents.

作者信息

Draffan Alistair G, Frey Barbara, Pool Brett, Gannon Carlie, Tyndall Edward M, Lilly Michael, Francom Paula, Hufton Richard, Halim Rosliana, Jahangiri Saba, Bond Silas, Nguyen Van T T, Jeynes Tyrone P, Wirth Veronika, Luttick Angela, Tilmanis Danielle, Thomas Jesse D, Pryor Melinda, Porter Kate, Morton Craig J, Lin Bo, Duan Jianmin, Kukolj George, Simoneau Bruno, McKercher Ginette, Lagacé Lisette, Amad Ma'an, Bethell Richard C, Tucker Simon P

机构信息

Biota Scientific Management Pty. Ltd. , 10/585 Blackburn Road, Notting Hill, Victoria 3168, Australia.

Research and Development, Boehringer Ingelheim (Canada), Ltd. , 2100 rue Cunard, Laval, Québec H7S 2G5, Canada.

出版信息

ACS Med Chem Lett. 2014 Apr 10;5(6):679-84. doi: 10.1021/ml500077j. eCollection 2014 Jun 12.

DOI:10.1021/ml500077j
PMID:24944743
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4060939/
Abstract

Nucleoside analogues have long been recognized as prospects for the discovery of direct acting antivirals (DAAs) to treat hepatitis C virus because they have generally exhibited cross-genotype activity and a high barrier to resistance. C-Nucleosides have the potential for improved metabolism and pharmacokinetic properties over their N-nucleoside counterparts due to the presence of a strong carbon-carbon glycosidic bond and a non-natural heterocyclic base. Three 2'CMe-C-adenosine analogues and two 2'CMe-guanosine analogues were synthesized and evaluated for their anti-HCV efficacy. The nucleotide triphosphates of four of these analogues were found to inhibit the NS5B polymerase, and adenosine analogue 1 was discovered to have excellent pharmacokinetic properties demonstrating the potential of this drug class.

摘要

核苷类似物长期以来一直被视为发现用于治疗丙型肝炎病毒的直接作用抗病毒药物（DAA）的潜在药物，因为它们通常表现出跨基因型活性以及对耐药性的高屏障。由于存在强碳 - 碳糖苷键和非天然杂环碱基，C - 核苷相比于它们的N - 核苷类似物具有改善代谢和药代动力学性质的潜力。合成了三种2'CMe - C - 腺苷类似物和两种2'CMe - 鸟苷类似物，并对其抗丙型肝炎病毒疗效进行了评估。发现其中四种类似物的三磷酸核苷酸可抑制NS5B聚合酶，并且发现腺苷类似物1具有优异的药代动力学性质，证明了这类药物的潜力。